Synergy Pharmaceuticals:

Is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. They are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for their employees, and creating exceptional value for their shareholders. In Synergy Pharmaceuticals they have “pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders”. Synergy Pharmaceuticals (2018) They are based in New York, with research, technical operations and commercial offers in suburban Philadelphia. “Synergy [SGYP] became a public company in July 2008 and is currently listed on Nasdaq”. Synergy Pharmaceuticals (2018)

As a company Synergy values every aspect of business ranging from relationships “with customers to how we approach science and innovation, and to realizing our vision of a healthier future for patients”. Synergy Pharmaceuticals (2018)

Focus is placed on:

1. Quality
2. Honesty
3. Teamwork
4. Passion
5. Commitment

The role of their webiste is for brand orientation and relationship building, it is a way to build and sustain their brand image and create a community network for customers to visit. Synergy’s website is clear, quick and effective with a clear brand name tyring to “ignite change”. Synergy Pharmaceuticals (2018) They provide research and developmement which shows their involvement in research platforms while theraputic focus is also emphasized on their website. Along with that, Synergy is involved in alot of events and presentations easily located on their website along with press release articles.

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced today that “the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing Luoxin exclusive rights to develop and commercialize Synergy’s lead product TRULANCE^® (plecanatide) (Trulance is a once-daily tablet) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau”. Business Wire (2018) It is very clear that “Luoxin is a leading pharmaceutical company in China with strong capabilities for successfully delivering TRULANCE to patients in its market”, as stated by Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc. Business Wire (2018)

Luoxin on the other hand is a “pharmaceutical company in China establihsed in 1988 and engages in pharmaceutical research and development, manufacture, sales, and healthcare services”. Business Wire (2018)

Significantly, Synergy Pharmaceuticals is a B2B company acting as a mediator for consumers while through the use of their executive partners their reach out to consumers and with this in order to optimize the value of TRULANCE on August 7, 2018, “Synergy  announced that Express Scripts, a leading U.S. pharmacy benefit manager, will add TRULANCE to its 2019 National Preferred Formulary List, effective January 1, 2019″. Synergy Pharmaceuticals(2018) This is a very important highlight for Synergy since it marks the value of their product.

Synergy Pharmaceuticals has various strong partnerships and these include:

1) Luoxin Pharmaceutical Group Co., Ltd.,

2) Cipher Pharmaceuticals

3) The National Cancer Institute (NCI)

Other than that Synergy reported “TRULANCE net sales were $8.6 million in the first quarter of 2018 compared to net sales of $9.4 million during the fourth quarter of 2017. TRULANCE first quarter net sales of $8.6 million increased by 18% compared to fourth quarter of 2017 adjusted net sales (non-GAAP) of $7.3 million”. Synergy Pharmaceuticals (2018)

With all these in mind it is important to notice that Synergy has a huge input in the industry and provides significant expertise in order to help patients by providing novel treatment options for their patients and their healthcare providers.

-This is a student blog post on company analysis.-